Treatments with either Cxcl1 or IL-1β restored the mature β cell phenotype and rescued MyD88-deficient mice from glucose intolerance, indicating the Cxcl1/IL-1β axis as a potential therapeutic target. This evidence concerns the gene IL1B and Glucose intolerance.